Clinical profile and problems of management of 108 cases of germ cell tumours of testis at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 1985-1990

Raina, Vinod; Shukla, N.K.; Rath, GK; Gupta, Nidhi; Mc, Mishra; Chaterjee, TK; Kripalani, A K

doi:10.1038/bjc.1993.105

Cited by 7 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence incidence of bladder cancer appears to be low in Sri Lanka compared to rates in other South Asian countries such as India (3.2 per 100 000) and Karachi, Pakistan (8.9 per 100 000) [ 4 , 5 ]. In Delhi, India, the age adjusted bladder cancer incidence reaches 5.8/100 000 [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Pathological Characteristics of Primary Bladder Carcinoma Treated at a Tertiary Care Hospital and Changing Demographics of Bladder Cancer in Sri Lanka

Sasikumar

Wijayarathna

Karunaratne

et al. 2016

Advances in Urology

View full text Add to dashboard Cite

Objectives. The aim was to compare demographics and pathological features of bladder carcinoma treated in a urology unit with findings of previous studies done in Sri Lanka. Materials and Methods. Data of newly diagnosed patients with bladder cancer in a tertiary referral centre from 2011 to 2014 were analysed. Data on bladder cancers diagnosed from 1993 to 2014 were obtained from previous publications and Sri Lanka Cancer Registry. Results. There were 148 patients and mean age was 65 years. Male to female ratio was 4.1 : 1. Urothelial carcinoma (UC) was found in 89.2% of patients. Muscle invasion was noted in 35% of patients compared to 48.4% two decades ago. In patients with UC, 16.5% were found to have pT1 high grade tumour. It was 5.3% from 1993 to 2000. Pure squamous cell carcinoma was found in 8.1% of patients while primary or de novo carcinoma in situ (not associated with high grade pT1 tumours) was seen in one patient only. Conclusions. The percentage of squamous carcinoma is higher among Sri Lankan patients while primary carcinoma in situ is a rarity. The percentage of muscle invasive disease has decreased while the percentage of pT1 high grade tumours has increased during the last two decades in Sri Lanka.

show abstract

Section: Introductionmentioning

confidence: 99%

Pathological Characteristics of Primary Bladder Carcinoma Treated at a Tertiary Care Hospital and Changing Demographics of Bladder Cancer in Sri Lanka

Sasikumar

Wijayarathna

Karunaratne

et al. 2016

Advances in Urology

View full text Add to dashboard Cite

show abstract

“…Even in developed nations, the multidisciplinary management of these tumours poses a challenge. Though GCTs among the adolescent and young population are treated with a curative intent worldwide, the additional challenges faced in LMIC settings are unique and include delayed presentation, higher proportion of treatment abandonment, poor follow up and limited access to more advanced salvage treatments like HDT and ASCT (HDT/SCT) [6][7][8]11]. Our study reports real world outcomes among patients with PMGCTs in a LMIC setting.…”

Section: Discussionmentioning

confidence: 96%

Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting

Joel

Mathew

Andugala

et al. 2021

ecancer

View full text Add to dashboard Cite

Purpose: Primary mediastinal germ cell tumours (PMGCTs) are rare; with limited data available about their outcomes and optimal treatment in the low middle income countries setting. We studied the clinical profile of patients with PMGCT treated at our centre in order to estimate their survival outcomes and to identify prognostic factors affecting the same. Patients and methods: Fifty-seven patients with PMGCTs treated between April 2001 and June 2019 were included. Baseline characteristics, details of first line chemotherapy, response rates, toxicity and surgical outcomes were noted. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Results: Among 57 male patients (seminoma = 20 and nonseminomatous = 37), the median follow-up was 10 months (range: 1-120 months). For mediastinal seminoma, 9 (45%) and 11 (55%) patients had good and intermediate risk disease, respectively. Nineteen patients (95%) received BEP (Bleomycin, etoposide and cisplatin) chemotherapy. 94.7% had partial responses and median event-free survival was not reached. All patients were alive and disease free at 2 years. For primary mediastinal nonseminomatous germ cell tumours (PMNSGCTs), all patients were poor risk. Thirty-four (91.8%) received BEP/ EP chemotherapy as first line. Responses were PRM+ (partial response with elevated markers) in 7 (20.5%) and PRM− in 12 (35.2%). The incidence of febrile neutropenia was 50% and 55.8% in seminole and PMNSGCT, respectively. The median OS was 9.06 months and median PFS was 4.63 months for PMNSGCT. The proportion of patients alive at 1 year and 2 years were 35% and 24.3%, respectively. Conclusion: Primary mediastinal seminomas are rarer and have better survival outcomes. Treatment of PMNSGCT is still a challenge and is associated with poorer survival outcomes.

show abstract

Acceptance of Cancer Screening

Rimer

Demark‐Wahnefried

Egert

1997

Handbook of Health Behavior Research II

View full text Add to dashboard Cite

Clinical profile and problems of management of 108 cases of germ cell tumours of testis at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 1985-1990

Abstract: Summary A retrospective analysis of 108 cases of primary germ cell tumours of testis seen over a 6 year

Cited by 7 publications

References 5 publications

Pathological Characteristics of Primary Bladder Carcinoma Treated at a Tertiary Care Hospital and Changing Demographics of Bladder Cancer in Sri Lanka

Pathological Characteristics of Primary Bladder Carcinoma Treated at a Tertiary Care Hospital and Changing Demographics of Bladder Cancer in Sri Lanka

Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting

Acceptance of Cancer Screening

Contact Info

Product

Resources

About